Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Häufige urologisch-sexualmedizinische Themen in der Praxis sind das Thema des MMW-Webinars am 5. Juni von 17.30 bis 19 Uhr. Konkret geht es um die Frage, wann bei Harnwegsinfektionen auf Antibiotika verzichtet werden kann, und um ein Update zur Therapie von Libido- und Potenzstörungen des Mannes. Der dritte Vortrag behandelt sexuell übertragbare Krankheiten. Stellen Sie Ihre Fragen an die Experten und sammeln Sie 2 CME-Punkte. Jetzt gleich anmelden!
Erweiterte Suche
Anmelden
nach oben
Supportive Care in Cancer
Erschienen in: Supportive Care in Cancer 10/2006

01.10.2006 | Review Article

Prognostic factors in patients with recently diagnosed incurable cancer: a systematic review

verfasst von: Catherine A. Hauser, Martin R. Stockler, Martin H. N. Tattersall

Erschienen in: Supportive Care in Cancer | Ausgabe 10/2006

Einloggen, um Zugang zu erhalten

Abstract

Goals of work

To review the literature and develop a conceptual framework about prognostic factors for people presenting to medical oncologists with recently diagnosed incurable cancer.

Materials and methods

Medline was searched from January 2000 to October 2003 to identify articles testing associations between clinical or laboratory variables and survival time in adults with advanced solid tumours and median survival of 3 to 24 months. We recorded how frequently prognostic factors were significantly associated with survival in univariable and multivariable analyses.

Results

There were 53 studies included. The factors associated with survival were organised into four categories related to attributes of the host the tumour, the treatment and the interactions between host, tumour and treatment (symptoms, quality of life, performance status and laboratory tests). Co-morbidity was consistently associated with shorter survival. Age and gender were not consistently associated with survival duration, except in lung cancer where females survived longer. Tumour-related factors associated with shorter survival included primary tumour (lung), metastatic site (liver, brain and visceral) and disease extent. Symptoms associated with shorter survival included those of the anorexia–cachexia syndrome, dyspnoea, pain and impaired physical well being. Performance status was strongly associated with survival in most studies. Laboratory tests associated with shorter survival included anaemia, thrombocytopenia, hypoalbuminaemia and elevated serum levels of both alkaline phosphatase and lactate dehydrogenase.

Conclusion

Prognostic factors in patients with advanced cancer can be conceptualised as attributes of the host, tumour, treatment and interactions between the three reflected in symptoms, quality of life performance status and laboratory tests.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Christakis NA, Lamont EB (2000) Extent and determinants of error in doctors’ prognoses in terminally ill patients: prospective cohort study. BMJ 320(7233):469–472PubMedCrossRef
2.
Glare P, Virik K, Jones M et al (2003) A systematic review of physicians’ survival predictions in terminally ill cancer patients. BMJ 327(7408):195PubMedCrossRef
3.
Chow E, Harth T, Hruby G et al (2001) How accurate are physicians’ clinical predictions of survival and the available prognostic tools in estimating survival times in terminally ill cancer patients? A systematic review. Clin Oncol (R Coll Radiol) 13(3):209–218
4.
Vigano A, Dorgan M, Buckingham J et al (2000) Survival prediction in terminal cancer patients: a systematic review of the medical literature. Palliat Med 14(5):363–374PubMedCrossRef
5.
Maltoni M, Amadori D (2002) Prognosis in advanced cancer. Hematol Oncol Clin North Am 16(3):715–729PubMedCrossRef
6.
Morita T, Tsunoda J, Inoue S, Chihara S (1999) The palliative prognostic index: a scoring system for survival prediction of terminally ill cancer patients. Support Care Cancer 7(3):128–133PubMedCrossRef
7.
Pirovano M, Maltoni M, Nanni O et al (1999) A new palliative prognostic score: a first step for the staging of terminally ill cancer patients. Italian multicenter and study group on palliative care. J Pain Symptom Manage 17(4):231–239PubMedCrossRef
8.
Glare P, Virik K (2001) Independent prospective validation of the PaP score in terminally ill patients referred to a hospital-based palliative medicine consultation service. J Pain Symptom Manage 22(5):891–898PubMedCrossRef
9.
Milsted RA, Tattersall MH, Fox RM, Woods RL (1980) Cancer chemotherapy—what have we achieved? Lancet 1(8182):1343–1346PubMedCrossRef
10.
Tattersall MH, Thomas H (1999) Recent advances: oncology. BMJ 318(7181):445–448PubMed
11.
Radzikowska E, Glaz P, Roszkowski K (2002) Lung cancer in women: age, smoking, histology, performance status, stage, initial treatment and survival. Population-based study of 20561 cases. Ann Oncol13(7):1087–1093PubMedCrossRef
12.
Werner-Wasik M, Scott C, Cox JD et al (2000) Recursive partitioning analysis of 1999 Radiation Therapy Oncology Group (RTOG) patients with locally-advanced non-small-cell lung cancer (LA-NSCLC): identification of five groups with different survival. Int J Radiat Oncol Biol Phys 48(5):1475–1482PubMed
13.
Buccheri G, Torchio P, Ferrigno D (2003) Plasma levels of D-dimer in lung carcinoma: clinical and prognostic significance. Cancer 97(12):3044–3052PubMedCrossRef
14.
Le Chevalier TBD, Soria JC, Douillard JY et al (2001) Long term analysis of survival in the European randomized trial comparing vinorelbine/cisplatin to vindesine/cisplatin and vinorelbine alone in advanced non-small cell lung cancer. Oncologist 6(Suppl 1):8–11PubMedCrossRef
15.
Eton DT, Fairclough DL, Cella D et al (2003) Early change in patient-reported health during lung cancer chemotherapy predicts clinical outcomes beyond those predicted by baseline report: results from Eastern Cooperative Oncology Group Study 5592. J Clin Oncol 21(8):1536–1543PubMedCrossRef
16.
Ando M, Ando Y, Hasegawa Y et al (2001) Prognostic value of performance status assessed by patients themselves, nurses, and oncologists in advanced non-small cell lung cancer. Br J Cancer 85(11):1634–1639PubMedCrossRef
17.
Nakahara Y, Mochizuki Y, Miyamoto Y et al (2002) Mental state as a possible independent prognostic variable for survival in patients with advanced lung carcinoma. Cancer 94(11):3006–3015PubMedCrossRef
18.
Kodani T, Ueoka H, Kiura K et al (2002) A phase III randomized trial comparing vindesine and cisplatin with or without ifosfamide in patients with advanced non-small-cell lung cancer: long-term follow-up results and analysis of prognostic factors. Lung Cancer 36(3):313–319PubMedCrossRef
19.
MacRae R, Shyr Y, Johnson D, Choy H (2002) Declining hemoglobin during chemoradiotherapy for locally advanced non-small cell lung cancer is significant. Radiother Oncol 64(1):37–40PubMedCrossRef
20.
Firat S, Byhardt RW, Gore E (2002) Comorbidity and Karnofksy performance score are independent prognostic factors in stage III non-small-cell lung cancer: an institutional analysis of patients treated on four RTOG studies. Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys 54(2):357–364PubMed
21.
Orditura M, De Vita F, Catalano G et al (2002) Elevated serum levels of interleukin-8 in advanced non-small cell lung cancer patients: relationship with prognosis. J Interferon Cytokine Res 22(11):1129–1135PubMedCrossRef
22.
Orditura M, Romano C, De Vita F et al (2000) Behaviour of interleukin-2 serum levels in advanced non-small-cell lung cancer patients: relationship with response to therapy and survival. Cancer Immunol Immunother 49(10):530–536PubMedCrossRef
23.
McMillan DC, Elahi MM, Sattar N et al (2001) Measurement of the systemic inflammatory response predicts cancer-specific and non-cancer survival in patients with cancer. Nutr Cancer 41(1–2):64–69PubMedCrossRef
24.
Sloan JA, Loprinzi CL, Laurine JA et al (2001) A simple stratification factor prognostic for survival in advanced cancer: the good/bad/uncertain index. J Clin Oncol 19(15):3539–3546PubMed
25.
Chow E, Fung K, Panzarella T et al (2002) A predictive model for survival in metastatic cancer patients attending an outpatient palliative radiotherapy clinic. Int J Radiat Oncol Biol Phys 53(5):1291–1302PubMedCrossRef
26.
Vigano A, Bruera E, Jhangri GS et al (2000) Clinical survival predictors in patients with advanced cancer. Arch Intern Med 160(6):861–868PubMedCrossRef
27.
Shadbolt B, Barresi J, Craft P (2002) Self-rated health as a predictor of survival among patients with advanced cancer. J Clin Oncol 20(10):2514–2519PubMedCrossRef
28.
Bachelot T, Ray-Coquard I, Catimel G et al (2000) Multivariable analysis of prognostic factors for toxicity and survival for patients enrolled in phase I clinical trials. Ann Oncol 11(2):151–156PubMedCrossRef
29.
De Vita F, Orditura M, Galizia G et al (2000) Serum interleukin-10 is an independent prognostic factor in advanced solid tumors. Oncol Rep 7(2):357–361PubMed
30.
Gamburg ES, Regine WF, Patchell RA et al (2000) The prognostic significance of midline shift at presentation on survival in patients with glioblastoma multiforme. Int J Radiat Oncol Biol Phys 48(5):1359–1362PubMed
31.
Kohne CH, Cunningham D, Di CF et al (2002) Clinical determinants of survival in patients with 5-fluorouracil-based treatment for metastatic colorectal cancer: results of a multivariate analysis of 3825 patients. Ann Oncol 13(2):308–317PubMedCrossRef
32.
Massacesi C, Norman A, Price T et al (2000) A clinical nomogram for predicting long-term survival in advanced colorectal cancer. Eur J Cancer 36(16):2044–2052PubMedCrossRef
33.
Maisey NR, Norman A, Watson M et al (2002) Baseline quality of life predicts survival in patients with advanced colorectal cancer. Eur J Cancer 38(10):1351–1357PubMedCrossRef
34.
Bensmaine MA, Marty M, de Gramont A et al (2001) Factors predicting efficacy of oxaliplatin in combination with 5-fluorouracil (5-FU) +/−folinic acid in a compassionate-use cohort of 481 5-FU-resistant advanced colorectal cancer patients. Br J Cancer 85(4):509–517PubMedCrossRef
35.
Massacesi C, Pistilli B, Valeri M et al (2002) Predictors of short-term survival and progression to chemotherapy in patients with advanced colorectal cancer treated with 5-fluorouracil-based regimens. Am J Clin Oncol 25(2):140–148PubMedCrossRef
36.
Ruo L, Gougoutas C, Paty PB et al (2003) Elective bowel resection for incurable stage IV colorectal cancer: prognostic variables for asymptomatic patients. J Am Coll Surg 196(5):722–728PubMedCrossRef
37.
Yuste AL, Aparicio J, Segura A et al (2003) Analysis of clinical prognostic factors for survival and time to progression in patients with metastatic colorectal cancer treated with 5-fluorouracil-based chemotherapy. Clin Colorectal Cancer 2(4):231–234PubMedCrossRef
38.
Alexandre J, Bleuzen P, Bonneterre J et al (2000) Factors predicting for efficacy and safety of docetaxel in a compassionate-use cohort of 825 heavily pretreated advanced breast cancer patients. J Clin Oncol 18(3):562–573PubMed
39.
Luoma ML, Hakamies-Blomqvist L, Sjostrom J et al (2003) Prognostic value of quality of life scores for time to progression (TTP) and overall survival time (OS) in advanced breast cancer. Eur J Cancer 39(10):1370–1376PubMedCrossRef
40.
Kramer JA, Curran D, Piccart M et al (2000) Identification and interpretation of clinical and quality of life prognostic factors for survival and response to treatment in first-line chemotherapy in advanced breast cancer. Eur J Cancer 36(12):1498–1506PubMedCrossRef
41.
Wyld L, Gutteridge E, Pinder SE et al (2003) Prognostic factors for patients with hepatic metastases from breast cancer. Br J Cancer 89(2):284–290PubMedCrossRef
42.
Shimozuma K, Sonoo H, Ichihara K, Tanaka K (2000) The prognostic value of quality-of-life scores: preliminary results of an analysis of patients with breast cancer. Surg Today 30(3):255–261PubMedCrossRef
43.
Engelken FJ, Bettschart V, Rahman MQ et al (2003) Prognostic factors in the palliation of pancreatic cancer. Eur J Surg Oncol 29(4):368–373PubMedCrossRef
44.
Ridwelski K, Meyer F, Ebert M et al (2001) Prognostic parameters determining survival in pancreatic carcinoma and, in particular, after palliative treatment. Dig Dis 19(1):85–92PubMedCrossRef
45.
Tas F, Aykan F, Alici S et al (2001) Prognostic factors in pancreatic carcinoma: serum LDH levels predict survival in metastatic disease. Am J Clin Oncol 24(6):547–550PubMedCrossRef
46.
Ueno H, Okada S, Okusaka T, Ikeda M (2000) Prognostic factors in patients with metastatic pancreatic adenocarcinoma receiving systemic chemotherapy. Oncology 59(4):296–301PubMedCrossRef
47.
Ikeda M, Okada S, Tokuuye K et al (2001) Prognostic factors in patients with locally advanced pancreatic carcinoma receiving chemoradiotherapy. Cancer 91(3):490–495PubMedCrossRef
48.
Roychowdhury DF, Hayden A, Liepa AM (2003) Health-related quality-of-life parameters as independent prognostic factors in advanced or metastatic bladder cancer. J Clin Oncol 21(4):673–678PubMedCrossRef
49.
Sengelov L, Kamby C, von der Maase H (2001) Metastatic urothelial cancer: evaluation of prognostic factors and change in prognosis during the last twenty years. Eur Urol 39(6):634–642PubMedCrossRef
50.
Stadler WM, Hayden A, von der Maase H et al (2002) Long-term survival in phase II trials of gemcitabine plus cisplatin for advanced transitional cell cancer. Urol Oncol 7(4):153–157PubMedCrossRef
51.
Sengelov L, Kamby C, Geertsen P et al (2000) Predictive factors of response to cisplatin-based chemotherapy and the relation of response to survival in patients with metastatic urothelial cancer. Cancer Chemother Pharmacol 46(5):357–364PubMedCrossRef
52.
Bellmunt J, Albanell J, Paz-Ares L et al (2002) Pretreatment prognostic factors for survival in patients with advanced urothelial tumors treated in a phase I/II trial with paclitaxel, cisplatin, and gemcitabine. Cancer 95(4):751–757PubMedCrossRef
53.
Fujisaki S, Tomita R, Nezu T et al (2001) Prognostic studies on gastric cancer with concomitant liver metastases. Hepatogastroenterology 48(39):892–894PubMed
54.
Louvet C, Carrat F, Mal F et al (2003) Prognostic factor analysis in advanced gastric cancer patients treated with hydroxyurea, leucovorin, 5-fluorouracil, and cisplatin (HLFP regimen). Cancer Investig 21(1):14–20CrossRef
55.
O’Gorman P, McMillan DC, McArdle CS (2000) Prognostic factors in advanced gastrointestinal cancer patients with weight loss. Nutr Cancer 37(1):36–40PubMedCrossRef
56.
De Vita F, Romano C, Orditura M et al (2001) Interleukin-6 serum level correlates with survival in advanced gastrointestinal cancer patients but is not an independent prognostic indicator. J Interferon Cytokine Res 21(1):45–52PubMedCrossRef
57.
Shimada H, Kitabayashi H, Nabeya Y et al (2003) Treatment response and prognosis of patients after recurrence of esophageal cancer. Surgery 133(1):24–31PubMedCrossRef
58.
Ogawa K, Toita T, Sueyama H et al (2002) Brain metastases from esophageal carcinoma: natural history, prognostic factors, and outcome. Cancer 94(3):759–764PubMedCrossRef
59.
Dowling AJ, Czaykowski PM, Krahn MD et al (2000) Prostate specific antigen response to mitoxantrone and prednisone in patients with refractory prostate cancer: prognostic factors and generalizability of a multicenter trial to clinical practice. J Urol 163(5):1481–1485PubMedCrossRef
60.
Hernes EH, Linja M, Fossa SD et al (2000) Hormone-resistant prostate cancer with symptomatic pelvic tumours: patient survival and prognostic factors. BJU Int 86(3):240–247PubMedCrossRef
61.
Keilholz U, Martus P, Punt CJ et al (2002) Prognostic factors for survival and factors associated with long-term remission in patients with advanced melanoma receiving cytokine-based treatments: second analysis of a randomised EORTC Melanoma Group trial comparing interferon-alpha2a (IFNalpha) and interleukin 2 (IL-2) with or without cisplatin. Eur J Cancer 38(11):1501–1511PubMedCrossRef
62.
Scholz HS, Benedicic C, Haas J et al (2001) Stage IV ovarian cancer: prognostic factors and survival beyond 5 years. Anticancer Res 21(5):3729–3732PubMed
63.
Ljungberg B, Landberg G, Alamdari FI (2000) Factors of importance for prediction of survival in patients with metastatic renal cell carcinoma, treated with or without nephrectomy. Scand J Urol Nephrol 34(4):246–251PubMedCrossRef
64.
Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40(5):373–383PubMedCrossRef
65.
Bruera E (1997) ABC of palliative care. Anorexia, cachexia, and nutrition. BMJ 315(7117):1219–1222PubMed
66.
McMillan DC, Watson WS, O’Gorman P et al (2001) Albumin concentrations are primarily determined by the body cell mass and the systemic inflammatory response in cancer patients with weight loss. Nutr Cancer 39(2):210–213PubMedCrossRef
67.
Sorensen HT, Mellemkjaer L, Olsen JH, Baron JA (2000) Prognosis of cancers associated with venous thromboembolism. N Engl J Med 343(25):1846–1850PubMedCrossRef
68.
Yun YH, Heo DS, Heo BY et al (2001) Development of terminal cancer prognostic score as an index in terminally ill cancer patients. Oncol Rep 8(4):795–800PubMed
Metadaten
Titel
Prognostic factors in patients with recently diagnosed incurable cancer: a systematic review
verfasst von
Catherine A. Hauser
Martin R. Stockler
Martin H. N. Tattersall
Publikationsdatum
01.10.2006
Verlag
Springer-Verlag
Erschienen in
Supportive Care in Cancer / Ausgabe 10/2006
Print ISSN: 0941-4355
Elektronische ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-006-0079-9

Weitere Artikel der Ausgabe 10/2006

Supportive Care in Cancer 10/2006 Zur Ausgabe

Forthcoming Meetings

Forthcoming meetings

Original Article

Decision making in palliative radiation therapy: reframing hope in caregivers and patients with brain metastases

Original Article

Ways of understanding the encounter with head and neck cancer patients in the hospital dental team—a phenomenographic study

Original Article

Clinical and economic impact of epoetin in adjuvant-chemotherapy for breast cancer

Supportive Care International

Bringing palliative care to a Canadian cancer center: the palliative care program at Princess Margaret Hospital

Special Article

The clinical significance of quality of life assessments in oncology: a summary for clinicians

Neu im Fachgebiet Onkologie

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

15% bedauern gewählte Blasenkrebs-Therapie

29.05.2024 Urothelkarzinom Nachrichten

Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

28.05.2024 Nebenwirkungen der Krebstherapie Nachrichten

Kardiotoxische Nebenwirkungen einer Therapie mit Immuncheckpointhemmern mögen selten sein – wenn sie aber auftreten, wird es für Patienten oft lebensgefährlich. Voruntersuchung und Monitoring sind daher obligat.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise